Fiera Capital Corp Increases Position in Immunocore Holdings PLC Sponsored ADR $IMCR

Fiera Capital Corp lifted its position in Immunocore Holdings PLC Sponsored ADR (NASDAQ:IMCR) by 31.4% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 1,044,831 shares of the company’s stock after purchasing an additional 249,674 shares during the period. Fiera Capital Corp owned about 2.07% of Immunocore worth $36,266,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds and other institutional investors have also recently modified their holdings of IMCR. Millennium Management LLC increased its stake in shares of Immunocore by 334.3% in the third quarter. Millennium Management LLC now owns 1,265,965 shares of the company’s stock worth $45,993,000 after purchasing an additional 974,463 shares in the last quarter. Bellevue Group AG grew its stake in Immunocore by 14.5% during the third quarter. Bellevue Group AG now owns 2,796,803 shares of the company’s stock valued at $101,608,000 after acquiring an additional 354,973 shares in the last quarter. Armistice Capital LLC grew its stake in Immunocore by 21.5% during the third quarter. Armistice Capital LLC now owns 824,000 shares of the company’s stock valued at $29,936,000 after acquiring an additional 146,000 shares in the last quarter. Candriam S.C.A. grew its stake in Immunocore by 100.1% during the third quarter. Candriam S.C.A. now owns 269,729 shares of the company’s stock valued at $9,799,000 after acquiring an additional 134,950 shares in the last quarter. Finally, Marshall Wace LLP grew its stake in Immunocore by 425.8% during the second quarter. Marshall Wace LLP now owns 146,610 shares of the company’s stock valued at $4,601,000 after acquiring an additional 118,728 shares in the last quarter. 84.50% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several research firms recently weighed in on IMCR. Jefferies Financial Group cut shares of Immunocore from a “buy” rating to a “hold” rating and cut their target price for the company from $48.00 to $33.00 in a research note on Monday, March 16th. Zacks Research raised shares of Immunocore from a “strong sell” rating to a “strong-buy” rating in a research note on Thursday, May 7th. Needham & Company LLC raised their target price on shares of Immunocore from $71.00 to $75.00 and gave the company a “buy” rating in a research note on Thursday, February 26th. Wall Street Zen raised shares of Immunocore from a “hold” rating to a “buy” rating in a research note on Saturday, May 9th. Finally, Mizuho set a $38.00 target price on shares of Immunocore in a research note on Thursday, February 19th. One research analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $56.71.

Immunocore Price Performance

Shares of IMCR stock opened at $27.79 on Tuesday. Immunocore Holdings PLC Sponsored ADR has a 52-week low of $27.56 and a 52-week high of $40.71. The company has a debt-to-equity ratio of 1.00, a quick ratio of 4.15 and a current ratio of 4.18. The firm has a market capitalization of $1.41 billion, a P/E ratio of -50.53 and a beta of 0.74. The stock has a 50 day moving average price of $29.72 and a 200 day moving average price of $32.58.

Immunocore (NASDAQ:IMCR) last issued its quarterly earnings results on Wednesday, May 6th. The company reported $0.25 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.26) by $0.51. Immunocore had a negative return on equity of 7.07% and a negative net margin of 6.68%.The firm had revenue of $106.68 million during the quarter, compared to analyst estimates of $145.20 million. During the same period last year, the company earned $0.10 EPS. Immunocore’s quarterly revenue was up 13.6% compared to the same quarter last year. As a group, sell-side analysts predict that Immunocore Holdings PLC Sponsored ADR will post 0.06 earnings per share for the current year.

Immunocore Profile

Immunocore plc is a clinical‐stage biotechnology company focused on the development of novel immunotherapies that harness the body’s own T‐cell response to treat cancer and infectious diseases. The company’s proprietary ImmTAC (immune mobilising monoclonal T‐cell receptors against cancer) platform utilizes engineered, soluble T‐cell receptor (TCR) molecules designed to recognise intracellular peptide–HLA complexes. By redirecting and activating T cells against disease‐associated targets, Immunocore aims to address malignancies and persistent viral infections with high unmet medical need.

The company’s most advanced candidate, tebentafusp, is a bispecific ImmTAC molecule that targets gp100, a melanoma‐associated antigen, and has received regulatory approval for the treatment of metastatic uveal melanoma.